Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
NEW YORK, Sept. 08, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Sequans Communications S.A. ("Sequans") (NYSE:SQNS) between April 29, 2016 and July 31, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To get more information go to:
http://www.zlk.com/pslra-sba/sequans-communications-s-a?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the Company was improperly recognizing revenue; and (2) as a result, certain public statements were materially false and misleading at all relevant times. On August 1, 2017, Sequans revealed that its revenue in the second quarter was negatively affected by a product return from an early 2016 sale related to the tablet business. When this news was announced, shares of Sequans declined in value materially, which caused investors harm.
If you suffered a loss in Sequans you have until October 10, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
